Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664003 | 0.79 | BACE1 (0.46) | BACE1 | |
| SCHEMBL16650249 | 0.75 | BACE1 (0.35) | BACE1 | |
| SCHEMBL10154566 | 0.73 | BACE1 (0.41) | BACE1 | |
| SCHEMBL4082804 | 0.73 | BACE1 (0.41) | BACE1 | |
| SCHEMBL16664735 | 0.71 | — | — | |
| SCHEMBL7938915 | 0.70 | BACE1 (0.35) | BACE1 | |
| SCHEMBL17655622 | 0.69 | BACE1 (0.46) | BACE1 | |
| SCHEMBL15606015 | 0.67 | BACE1 (0.53) | BACE1 | |
| SCHEMBL16664743 | 0.67 | — | — | |
| SCHEMBL4083038 | 0.66 | BACE1 (0.38) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, BACE2 | USP30 3982/4885BACE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.